Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 1999 March;41(1) > Panminerva Medica 1999 March;41(1):22-6





A Journal on Internal Medicine

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6




Panminerva Medica 1999 March;41(1):22-6

language: English

Plasma endo­the­lin-1 lev­els in ­patients ­with periph­er­al arte­ri­al occlu­sive dis­ease at dif­fer­ent Fontaine’s stag­es

Mangiafico R. A., Mal­a­ti­no L. S., San­ton­o­ci­to M., Sar­na­ta­ro F., Dell’Arte S., Mes­si­na R., San­tan­ge­lo B.

From the Institute of Internal Medicine “L. Condorelli”, University of Catania, Catania, Italy


Endothelin-1 (ET-1) is a ­potent vas­o­con­stric­tor and mit­o­gen­ic pep­tide pro­duced and secret­ed by endo­the­lial ­cells, ­which can ­play a poten­tial ­role in the devel­op­ment of ath­ero­scler­o­sis and in the pathoph­y­sio­lo­gy of extreme vaso­con­stric­tion of var­i­ous dis­eas­es.
Methods. To ­assess plas­ma endo­the­lin-1 (ET-1) con­cen­tra­tions in ­patients ­with periph­er­al arte­ri­al occlu­sive dis­ease (­PAOD) at dif­fer­ent Fontaine’s stag­es, we meas­ured plas­ma ET-1 by radio­im­mu­noas­say in 14 ­stage II ­PAOD ­patients (12 men, 2 wom­en; ­mean age 59.5±3.4 ­years) and in 10 ­stage III-IV ­PAOD ­patients (8 men, 2 wom­en, ­mean age 61.2±3.3 ­years). Ten nor­mal sub­jects (8 men, 2 wom­en, ­mean age 58.1±7.2 ­years) ­were con­sid­ered as con­trols.
Results. Mean (±SD) plas­ma ET-1 lev­els, as meas­ured by radio­im­mu­noas­say, ­were sig­nif­i­cant­ly great­er in ­stage II and ­stage III-IV ­PAOD ­patients ­than in con­trol sub­jects (4±0.4 and 5±0.4 ­pmol/L vs 2.5±0.6 ­pmol/L, respec­tive­ly, p<0.001). Furthermore, plas­ma lev­els of ET-1 in ­stage III-IV ­patients ­were sig­nif­i­cant­ly high­er ­than in ­stage II ­patients (p<0.01). A sig­nif­i­cant cor­re­la­tion was ­found ­between plas­ma ET-1 lev­els and num­ber of the arte­ri­al obstruc­tive ­lesions in ­PAOD ­patients (r=0.698; p<0.0001). No sig­nif­i­cant cor­re­la­tion was ­found ­between plas­ma ET-1 con­cen­tra­tions and ­pain-­free walk­ing dis­tance (r=-0.279, p=0.333, in ­stage II ­patients; r=0.137, p=0.705, in ­stage III-IV ­patients), and ­between plas­ma ET-1 lev­els and ­ankle/arm pres­sor ­index (r=0.032, p=0.913, in ­stage II ­patients; r=0.149, p=0.681, in ­stage III-IV ­patients) in the ­PAOD ­patients.
Conclusions. Raised plas­ma ET-1 ­could be a sen­sible mark­er ­both of endo­the­lial dam­age and dis­ease exten­sion. It ­could ­also pro­mote the pro­gres­sion of ath­e­ros­cle­rot­ic ­plaques and ­enhance the micro­vas­cu­lar resis­tance in ­these ­patients.

top of page

Publication History

Cite this article as

Corresponding author e-mail